Skip to main content
OpenTrials
Completed

NCT Number: NCT05104099

Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia

This study is a single-center propsective clinical trial to assess the ability of fluorescence techniques to mark high-grade vulvar intraepithelial neoplasias including high-grade vulvar squamous intraepithelial lesions and differentiated vulvar intraepithelial neoplasias following 3 hours Metvixia application.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vulvar Intraepithelial Neoplasia Differentiated Vulvar Intraepithelial Neoplasia Vulvar High Grade Squamous Intraepithelial Lesion

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Institut de Cancerologie de Lorraine

Vandœuvre-lès-Nancy, 54506, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 18 and over,
  • With isolated high-grade vulvar intraepithelial neoplasia OR associated with invasive cancer proven histologically by biopsy
  • Naive of any vulvovaginal treatment (surgery or radiotherapy)
  • No metastases
  • WHO <or equal to 3
  • Contraception method for women of childbearing potential
  • Patient affiliated to the social security scheme
  • Patient who understood, signed and dated the information note and the
  • consent form,
  • Patient able and willing to follow all study procedures in accordance with the protocol.

Exclusion criteria

  • History of hypersensitivity to the active substance methyl aminolevulinate or to any of the components of the drug (including peanut oil and refined almond oil), soybean or peanut
  • Ulceration or hyperpigmented lesions of the vulva
  • Patient with porphyria
  • Any previous vulvovaginal treatment (surgery or radiotherapy)
  • Metastatic disease
  • Patient undergoing treatment for any other invasive cancer
  • Pregnant, likely to be or breastfeeding patient
  • Patient deprived of liberty or under guardianship (including guardianship)
  • Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons.
  • Patient already included in another therapeutic trial with an experimental molecule,
  • Associated pathology that may prevent the patient from receiving METVIXIA application and light exposure.

Treatment and study plan

Metvixia Topical Cream

Drug

Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.

The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.

If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones.

Primary outcomes

  1. Evaluation of the success of the photodynamic diagnosis

    Time frame: 14 days (+/- 4 days) after the photodiagnosis

    Percentage of patients for whom the procedure successfully demonstrated high-grade vulvar intraepithelial neoplasias in fluorescence confirmed by biopsy.

    A patient will be considered successful if the presence or absence of fluorescence is consistent with the anatomo-pathological result, that means if her sample in the fluorescent area is positive in pathology and her sample in the non-fluorescent area is negative in anatomo-pathology.

    For a patient with no fluorescent labeling, the pathological results of her two samples must be negative for the patient to be considered successful. For a patient where the entire area fluoresces, the anatomo-pathological result of her two samples must be positive for the patient to be considered successful.

Secondary outcomes

  1. Sensitivity of the photodynamic diagnosis

    Time frame: 14 days (+/- 4 days) after the photodiagnosis

    The sensitivity will correspond to the number of fluorescent zones among the positive zones in anatomopathology.

  2. Specifity of the photodynamic diagnosis

    Time frame: 14 days (+/- 4 days) after the photodiagnosis

    The specificity will correspond to the number of non-fluorescent zones among the negative zones in anatomo-pathology.

  3. Intensity of flurescence evaluation

    Time frame: The day of the photo analysis with a specific software

    The fluorescence intensity will be measured by the signal to noise ratio, also called SNR (Signal to Noise Ratio) on photographie

  4. Tolerance evaluation

    Time frame: At inclusion, after applying the cream for 3 hours, before and immediately after the blue light exposition and at and the final study visite (14 days +/- 4 after the photodiagnosis)

    The tolerance of the application will be assessed by the number of grade 3 to 5 toxicity. The toxicity will be evaluated using the CTCAE v5 scale (Common Terminology for Adverse Events). The different grade on this scale is 1 to 5 (1 correspond to a asymptomatic or mild symptome, 2 to moderate toxicity, 3 to severe or medically significant but not immediately life-threatening toxicity, 4 to life-threatening consequences or urgent intervention indicated and 5 to the death related to the toxicity.

  5. Pain Evaluation

    Time frame: At inclusion, 1 hour after Metvixia application, before and immediately after the blue light exposition and at and the final study visite (14 days +/- 4 after the inclusion)

    Pain will be assessed using a numerical scale from 0 to 10 (0 corresponds to no pain and 10 to maximum pain)

Sponsors and collaborators

Lead sponsor

Institut de Cancérologie de Lorraine

Other

Registry information

Official study title

Evaluation of the Ability of PpIX Fluorescence to Mark High-grade Vulvar Intraepithelial Neoplasia Following the Methyl Aminolevulinate (Metvixia®) Application

Acronym: PhotodiVIN

Important dates

Study start
2021
Primary completion
2024
Study completion
2025
First posted
Nov 2, 2021
Registry last updated
Jul 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.